CHROMADEX CORP (CDXC) Fundamental Analysis & Valuation

NASDAQ:CDXC • US1710774076

7.87 USD
-0.07 (-0.88%)
At close: Mar 18, 2025
7.87 USD
0 (0%)
After Hours: 3/18/2025, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This CDXC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

6

Taking everything into account, CDXC scores 6 out of 10 in our fundamental rating. CDXC was compared to 57 industry peers in the Life Sciences Tools & Services industry. While CDXC has a great health rating, its profitability is only average at the moment. CDXC has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

6

1. CDXC Profitability Analysis

1.1 Basic Checks

  • In the past year CDXC was profitable.
  • CDXC had a positive operating cash flow in the past year.
  • CDXC had negative earnings in 4 of the past 5 years.
  • In multiple years CDXC reported negative operating cash flow during the last 5 years.
CDXC Yearly Net Income VS EBIT VS OCF VS FCFCDXC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M -20M -30M

1.2 Ratios

  • CDXC has a Return On Assets of 12.52%. This is amongst the best in the industry. CDXC outperforms 90.91% of its industry peers.
  • The Return On Equity of CDXC (18.55%) is better than 90.91% of its industry peers.
  • CDXC has a better Return On Invested Capital (12.13%) than 89.09% of its industry peers.
Industry RankSector Rank
ROA 12.52%
ROE 18.55%
ROIC 12.13%
ROA(3y)-9.02%
ROA(5y)-25.18%
ROE(3y)-18.83%
ROE(5y)-52.67%
ROIC(3y)N/A
ROIC(5y)N/A
CDXC Yearly ROA, ROE, ROICCDXC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

  • CDXC has a better Profit Margin (8.58%) than 74.55% of its industry peers.
  • The Operating Margin of CDXC (7.76%) is better than 63.64% of its industry peers.
  • The Gross Margin of CDXC (61.84%) is better than 87.27% of its industry peers.
  • In the last couple of years the Gross Margin of CDXC has grown nicely.
Industry RankSector Rank
OM 7.76%
PM (TTM) 8.58%
GM 61.84%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y2.12%
CDXC Yearly Profit, Operating, Gross MarginsCDXC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. CDXC Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), CDXC is creating some value.
  • CDXC has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for CDXC has been increased compared to 5 years ago.
  • Compared to 1 year ago, CDXC has an improved debt to assets ratio.
CDXC Yearly Shares OutstandingCDXC Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
CDXC Yearly Total Debt VS Total AssetsCDXC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

  • An Altman-Z score of 15.46 indicates that CDXC is not in any danger for bankruptcy at the moment.
  • CDXC has a Altman-Z score of 15.46. This is amongst the best in the industry. CDXC outperforms 100.00% of its industry peers.
  • There is no outstanding debt for CDXC. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 15.46
ROIC/WACC1.11
WACC10.97%
CDXC Yearly LT Debt VS Equity VS FCFCDXC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

  • CDXC has a Current Ratio of 3.57. This indicates that CDXC is financially healthy and has no problem in meeting its short term obligations.
  • CDXC's Current ratio of 3.57 is in line compared to the rest of the industry. CDXC outperforms 54.55% of its industry peers.
  • CDXC has a Quick Ratio of 3.06. This indicates that CDXC is financially healthy and has no problem in meeting its short term obligations.
  • CDXC has a Quick ratio (3.06) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 3.57
Quick Ratio 3.06
CDXC Yearly Current Assets VS Current LiabilitesCDXC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. CDXC Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 242.86% over the past year.
  • Looking at the last year, CDXC shows a quite strong growth in Revenue. The Revenue has grown by 19.17% in the last year.
  • The Revenue has been growing by 16.56% on average over the past years. This is quite good.
EPS 1Y (TTM)242.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5733.33%
Revenue 1Y (TTM)19.17%
Revenue growth 3Y13.87%
Revenue growth 5Y16.56%
Sales Q2Q%37.41%

3.2 Future

  • CDXC is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 43.55% yearly.
  • Based on estimates for the next years, CDXC will show a quite strong growth in Revenue. The Revenue will grow by 19.24% on average per year.
EPS Next Y19%
EPS Next 2Y41.63%
EPS Next 3Y43.55%
EPS Next 5YN/A
Revenue Next Year20.72%
Revenue Next 2Y18.22%
Revenue Next 3Y19.24%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
CDXC Yearly Revenue VS EstimatesCDXC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M
CDXC Yearly EPS VS EstimatesCDXC Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.2 -0.2 -0.4 -0.6

More info and screens

Find the best growth stocksShow best growing peers

4

4. CDXC Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 78.70, the valuation of CDXC can be described as expensive.
  • The rest of the industry has a similar Price/Earnings ratio as CDXC.
  • Compared to an average S&P500 Price/Earnings ratio of 26.46, CDXC is valued quite expensively.
  • A Price/Forward Earnings ratio of 66.13 indicates a quite expensive valuation of CDXC.
  • The rest of the industry has a similar Price/Forward Earnings ratio as CDXC.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 24.65, CDXC is valued quite expensively.
Industry RankSector Rank
PE 78.7
Fwd PE 66.13
CDXC Price Earnings VS Forward Price EarningsCDXC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • 61.82% of the companies in the same industry are more expensive than CDXC, based on the Enterprise Value to EBITDA ratio.
  • 65.45% of the companies in the same industry are more expensive than CDXC, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 51.22
EV/EBITDA 66.44
CDXC Per share dataCDXC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates CDXC does not grow enough to justify the current Price/Earnings ratio.
  • CDXC has a very decent profitability rating, which may justify a higher PE ratio.
  • CDXC's earnings are expected to grow with 43.55% in the coming years. This may justify a more expensive valuation.
PEG (NY)4.14
PEG (5Y)N/A
EPS Next 2Y41.63%
EPS Next 3Y43.55%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CDXC Dividend Analysis

5.1 Amount

  • No dividends for CDXC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

CDXC Fundamentals: All Metrics, Ratios and Statistics

CHROMADEX CORP

NASDAQ:CDXC (3/18/2025, 8:00:02 PM)

After market: 7.87 0 (0%)

7.87

-0.07 (-0.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)03-04
Earnings (Next)05-06
Inst Owners30.29%
Inst Owner Change1.22%
Ins Owners0.01%
Ins Owner Change0%
Market Cap611.89M
Revenue(TTM)99.60M
Net Income(TTM)8.55M
Analysts84.44
Price Target9.21 (17.03%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)415%
Min EPS beat(2)341.18%
Max EPS beat(2)488.82%
EPS beat(4)4
Avg EPS beat(4)242.8%
Min EPS beat(4)41.19%
Max EPS beat(4)488.82%
EPS beat(8)8
Avg EPS beat(8)150.17%
EPS beat(12)10
Avg EPS beat(12)102.99%
EPS beat(16)12
Avg EPS beat(16)74.16%
Revenue beat(2)2
Avg Revenue beat(2)6.44%
Min Revenue beat(2)6.07%
Max Revenue beat(2)6.81%
Revenue beat(4)2
Avg Revenue beat(4)-0.35%
Min Revenue beat(4)-9.39%
Max Revenue beat(4)6.81%
Revenue beat(8)4
Avg Revenue beat(8)1.29%
Revenue beat(12)4
Avg Revenue beat(12)-1.38%
Revenue beat(16)5
Avg Revenue beat(16)-2.29%
PT rev (1m)17.21%
PT rev (3m)17.21%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-2.77%
EPS NY rev (3m)-2.77%
Revenue NQ rev (1m)-1.81%
Revenue NQ rev (3m)-1.78%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 78.7
Fwd PE 66.13
P/S 6.14
P/FCF 51.22
P/OCF 50.53
P/B 13.27
P/tB 13.38
EV/EBITDA 66.44
EPS(TTM)0.1
EY1.27%
EPS(NY)0.12
Fwd EY1.51%
FCF(TTM)0.15
FCFY1.95%
OCF(TTM)0.16
OCFY1.98%
SpS1.28
BVpS0.59
TBVpS0.59
PEG (NY)4.14
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 12.52%
ROE 18.55%
ROCE 15.35%
ROIC 12.13%
ROICexc 104.84%
ROICexgc 111.73%
OM 7.76%
PM (TTM) 8.58%
GM 61.84%
FCFM 11.99%
ROA(3y)-9.02%
ROA(5y)-25.18%
ROE(3y)-18.83%
ROE(5y)-52.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y2.12%
F-Score7
Asset Turnover1.46
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 20.02%
Cap/Sales 0.16%
Interest Coverage 7726
Cash Conversion 141.79%
Profit Quality 139.72%
Current Ratio 3.57
Quick Ratio 3.06
Altman-Z 15.46
F-Score7
WACC10.97%
ROIC/WACC1.11
Cap/Depr(3y)21.85%
Cap/Depr(5y)22.95%
Cap/Sales(3y)0.27%
Cap/Sales(5y)0.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)242.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5733.33%
EPS Next Y19%
EPS Next 2Y41.63%
EPS Next 3Y43.55%
EPS Next 5YN/A
Revenue 1Y (TTM)19.17%
Revenue growth 3Y13.87%
Revenue growth 5Y16.56%
Sales Q2Q%37.41%
Revenue Next Year20.72%
Revenue Next 2Y18.22%
Revenue Next 3Y19.24%
Revenue Next 5YN/A
EBIT growth 1Y237.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year538.3%
EBIT Next 3Y140.93%
EBIT Next 5YN/A
FCF growth 1Y71.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y70.14%
OCF growth 3YN/A
OCF growth 5YN/A

CHROMADEX CORP / CDXC FAQ

What is the fundamental rating for CDXC stock?

ChartMill assigns a fundamental rating of 6 / 10 to CDXC.


Can you provide the valuation status for CHROMADEX CORP?

ChartMill assigns a valuation rating of 4 / 10 to CHROMADEX CORP (CDXC). This can be considered as Fairly Valued.


Can you provide the profitability details for CHROMADEX CORP?

CHROMADEX CORP (CDXC) has a profitability rating of 6 / 10.


Can you provide the financial health for CDXC stock?

The financial health rating of CHROMADEX CORP (CDXC) is 8 / 10.


What is the expected EPS growth for CHROMADEX CORP (CDXC) stock?

The Earnings per Share (EPS) of CHROMADEX CORP (CDXC) is expected to grow by 19% in the next year.